# **I** Impact of 26 Skin Diseases on the Risk of Non-Small

# 2 Cell Lung Cancer: A Mendelian Randomization Study

# 3 Using FinnGen R11 Data

- 4 Xingyuan Li<sup>1</sup>
- 5 Hui Li<sup>2</sup>
- 6
- <sup>7</sup> <sup>1</sup>Hunan University of Chinese Medicine, Changsha, Hunan, China 410208;
- <sup>8</sup> <sup>2</sup>Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde,
- 9 Hunan, China 415000
- 10
- 11 Xingyuan Li 1\*
- 12 Hui Li <sup>2\*</sup>
- 13 \*These authors contributed equally to this work
- 14
- 15 Correspondence: Hui Li
- 16 Hunan University of Chinese Medicine Affiliated Hospital of Changde, Changde,
- 17 Hunan, China 415000
- 18 Email: <u>786802170@qq.com</u>
- 19
- 20
- 21
- 22

#### 23 Abstract:

- 24 **Purpose:** To determine whether genetic predisposition to various skin diseases influences the
- 25 risk of non-small cell lung cancer (NSCLC) through Mendelian randomization (MR).
- 26 **Methods:** Single nucleotide polymorphisms (SNPs) associated with 26 skin diseases were
- 27 extracted from the FinnGen R11 dataset and underwent rigorous quality control. To evaluate the
- association between these skin diseases and the risk of non-small cell lung cancer (NSCLC), we
- 29 applied several analytical methods, including inverse-variance weighted (IVW), MR-Egger
- 30 regression, weighted median, Simple mode, and Weighted mode. The robustness of the findings
- 31 was further supported by assessing SNP heterogeneity with the Cochran Q test and evaluating
- 32 horizontal pleiotropy using the MR-Egger intercept test.
- 33 **Results:** Our study revealed that genetically predicted dermatitis herpetiformis (DH) was
- 34 significantly associated with an elevated risk of squamous cell carcinoma of the lung (SCC). Acne
- 35 was nominally linked to an increased risk of SCC. Additionally, rhinophyma (RHN), hidradenitis
- 36 suppurativa (HS), and DH were nominally associated with a higher risk of adenocarcinoma of the
- 37 lung (ADC). Of the remaining 22 skin diseases analyzed, 7 lacked sufficient instrumental
- variables to meet inclusion criteria. The other 15 skin diseases showed no statistically significant
   association with NSCLC.
- 40 **Conclusion:** This study ultimately analyzed the relationship between 19 skin diseases and
- 41 NSCLC at the genetic level, while 7 other skin diseases could not be analyzed due to insufficient
- 42 instrumental variables. Dermatitis herpetiformis and acne were associated with an increased risk
- 43 of squamous cell carcinoma of the lung. Additionally, rhinophyma, hidradenitis suppurativa, and
- 44 dermatitis herpetiformis were associated with an increased risk of adenocarcinoma of the lung.
- 45 Keywords: [Skin Diseases, Genetic level, Non-Small Cell Lung Cancer, Mendelian
- 46 randomization]

## 47 **1.Introduction**

48 Lung cancer is one of the most prevalent and deadly cancers worldwide<sup>[1]</sup>. Non-small
49 cell lung cancer (NSCLC) accounts for about 85% of lung cancer cases, highlighting the

| 51adenocarcinoma (ADC) and squamous cell carcinoma (SCC), representing 40% and 25-5230% of cases, respectively <sup>[2]</sup> . The development and progression of NSCLC are53influenced by genetic susceptibility, environmental factors, chronic inflammation, and54immune system dysregulation <sup>[3]</sup> . Despite extensive research, the etiology and55pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup> .56Skin diseases are a group of conditions that affect the skin, hair, nails, and associated57tissues. Several studies have already explored the physiological and pathological58connections between the skin and lungs, particularly focusing on the shared roles of59certain inflammatory pathways in lung and skin inflammation, as well as the relationship60between inflammation and lung tumors <sup>[5][47]</sup> . However, there are still many deficiencies61in the research on the correlation between specific skin diseases and lung diseases.62Previous Mendelian Randomization (MR) studies have also confirmed the association63between psoriasis and the risk of lung cancer <sup>[8][9]</sup> . Additionally, a Mendelian64randomization study demonstrated a relationship between psoriasis and pulmonary65fibrosis <sup>[10]</sup> . Building on these studies, it is logical to further investigate the relationship66between lung cancer and a broader range of skin diseases.67Based on current elinical practice, targeted therapy, immunotherapy, and radiotherapy for68lung cancer offen lead to varying degrees of adverse reactions in the skin and mucous69membranes <sup>[10][411]</sup> . T   | 50 | need for targeted research and therapies. The most common NSCLC subtypes are                                |
|---|----|---|
| <ul> <li>influenced by genetic susceptibility, environmental factors, chronic inflammation, and</li> <li>immune system dysregulation <sup>[3]</sup>. Despite extensive research, the etiology and</li> <li>pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup>.</li> <li>Skin diseases are a group of conditions that affect the skin, hair, nails, and associated</li> <li>tissues. Several studies have already explored the physiological and pathological</li> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5]+[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]+[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]+[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> </ul> | 51 | adenocarcinoma (ADC) and squamous cell carcinoma (SCC), representing 40% and 25-                            |
| <ul> <li>immune system dysregulation <sup>[3]</sup>. Despite extensive research, the etiology and</li> <li>pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup>.</li> <li>Skin diseases are a group of conditions that affect the skin, hair, nails, and associated</li> <li>tissues. Several studies have already explored the physiological and pathological</li> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5],[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8],[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10],[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> </ul>   | 52 | 30% of cases, respectively <sup>[2]</sup> . The development and progression of NSCLC are                    |
| <ul> <li>pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup>.</li> <li>Skin diseases are a group of conditions that affect the skin, hair, nails, and associated</li> <li>tissues. Several studies have already explored the physiological and pathological</li> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5],[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8],[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10],[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> </ul>   | 53 | influenced by genetic susceptibility, environmental factors, chronic inflammation, and                      |
| <ul> <li>Skin diseases are a group of conditions that affect the skin, hair, nails, and associated</li> <li>tissues. Several studies have already explored the physiological and pathological</li> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5]+[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> </ul>   | 54 | immune system dysregulation <sup>[3]</sup> . Despite extensive research, the etiology and                   |
| <ul> <li>tissues. Several studies have already explored the physiological and pathological</li> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5]+[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]+[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis<sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 55 | pathogenesis of lung cancer remain incompletely understood <sup>[4]</sup> .                                 |
| <ul> <li>connections between the skin and lungs, particularly focusing on the shared roles of</li> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5]+[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]+[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]+[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 56 | Skin diseases are a group of conditions that affect the skin, hair, nails, and associated                   |
| <ul> <li>certain inflammatory pathways in lung and skin inflammation, as well as the relationship</li> <li>between inflammation and lung tumors <sup>[5]-[7]</sup>. However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 57 | tissues. Several studies have already explored the physiological and pathological                           |
| <ul> <li>between inflammation and lung tumors <sup>[5]+[7]</sup>, However, there are still many deficiencies</li> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]+[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 58 | connections between the skin and lungs, particularly focusing on the shared roles of                        |
| <ul> <li>in the research on the correlation between specific skin diseases and lung diseases.</li> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 59 | certain inflammatory pathways in lung and skin inflammation, as well as the relationship                    |
| <ul> <li>Previous Mendelian Randomization (MR) studies have also confirmed the association</li> <li>between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 60 | between inflammation and lung tumors [5]-[7], However, there are still many deficiencies                    |
| <ul> <li>between psoriasis and the risk of lung cancer <sup>[8]-[9]</sup>, Additionally, a Mendelian</li> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 61 | in the research on the correlation between specific skin diseases and lung diseases.                        |
| <ul> <li>randomization study demonstrated a relationship between psoriasis and pulmonary</li> <li>fibrosis <sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 62 | Previous Mendelian Randomization (MR) studies have also confirmed the association                           |
| <ul> <li>fibrosis<sup>[10]</sup>. Building on these studies, it is logical to further investigate the relationship</li> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 63 | between psoriasis and the risk of lung cancer $\[8]$ - $\[9]$ , Additionally, a Mendelian                   |
| <ul> <li>between lung cancer and a broader range of skin diseases.</li> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 64 | randomization study demonstrated a relationship between psoriasis and pulmonary                             |
| <ul> <li>Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for</li> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 65 | fibrosis <sup>[10]</sup> . Building on these studies, it is logical to further investigate the relationship |
| <ul> <li>lung cancer often lead to varying degrees of adverse reactions in the skin and mucous</li> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 66 | between lung cancer and a broader range of skin diseases.   |
| <ul> <li>membranes <sup>[10]-[11]</sup>. Therefore, in a clinical setting, it is challenging to accurately observe</li> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>   | 67 | Based on current clinical practice, targeted therapy, immunotherapy, and radiotherapy for                   |
| <ul> <li>the relationship between skin diseases and lung cancer without these confounding factors.</li> <li>The MR method uses genetic variants as instrumental variables to mitigate confounding</li> </ul>  | 68 | lung cancer often lead to varying degrees of adverse reactions in the skin and mucous                       |
| 71 The MR method uses genetic variants as instrumental variables to mitigate confounding  | 69 | membranes [10]-[11]. Therefore, in a clinical setting, it is challenging to accurately observe              |
|   | 70 | the relationship between skin diseases and lung cancer without these confounding factors.                   |
| factors and provide stronger evidence of causal relationships <sup>[12]</sup> . Unlike clinical trials,   | 71 | The MR method uses genetic variants as instrumental variables to mitigate confounding                       |
|   | 72 | factors and provide stronger evidence of causal relationships [12]. Unlike clinical trials,                 |

3

- 73 MR can eliminate the influence of social environmental factors and treatment-related
- reffects on study results <sup>[13]-[14]</sup>, making it an effective tool for studying the genetic links
- 75 between skin diseases and lung cancer.
- 76

## **2. Information and methodology**

## 78 **2.1. Sources of information**

- 79 To utilize the most recent research data and ensure the uniformity of the study population, we
- 80 chose to obtain the instrumental variables from the June 2024 R11 data of the FinnGen database
- 81 (index (finngen.fi)). The final selected dataset is detailed in Table1.

## 82 **2.2.** Assumptions of the MR study

83 The Mendelian Randomization (MR) study is grounded in three key assumptions that ensure valid 84 causal inferences <sup>[15]</sup>. First, the relevance assumption requires that genetic instrumental variables 85 (GIVs) are strongly associated with the exposure factors. Second, the independence assumption 86 requires that GIVs are isolated from any confounders that might impact the correlation between 87 GIVs and outcomes. Third, the exclusion restriction assumption mandates that GIVs influence 88 outcomes solely through the exposure factors, with no direct impact on the outcomes themselves 89 (Fig1). In this study, skin diseases are considered the primary exposure factors, with squamous 90 cell carcinoma (SCC) and adenocarcinoma (ADC) of the lung as the outcomes of interest. The 91 objective is to analyze the potential causal impact of skin diseases on these two major subtypes 92 of non-small cell lung cancer (NSCLC).

## 93 **2. 3. Screening for genetic instrumental variables**

A stringent threshold of  $P < 5 \times 10^{-8}$  was used to identify single nucleotide polymorphisms (SNPs) significantly associated with exposure factors, qualifying them as genetic instrumental

96 variables (GIVs). This threshold selects only the most statistically significant SNPs, enhancing 97 the reliability of the Mendelian Randomization (MR) analysis. To minimize confounding from 98 linkage disequilibrium (LD), an r<sup>2</sup> value of 0.001 and a genetic window of 10,000 kilobases (kb) 99 were applied. 100 The strength of the GIVs was evaluated using the F statistic, calculated as F = (beta/se)<sup>2[16]</sup>. An F 101 value below 10 indicates a weak instrumental variable, potentially compromising the MR analysis. 102 Therefore, only SNPs with adequate F values were retained. 103 If the initial threshold of P < 5 × 10<sup>-8</sup> did not yield enough SNPs, it was relaxed to P < 5 × 10<sup>-6 [17]</sup> 104 to ensure sufficient genetic variants for analysis, especially for less common exposures. Despite 105 this adjustment, 7 skin diseases still lacked enough instrumental variables and were excluded

106 from the analysis.

#### 107 2. 4. Statistical analysis

108 The study employed a range of advanced statistical methods, including Inverse Variance 109 Weighted (IVW), MR-Egger regression, Weighted Median, Simple mode, and Weighted mode, to 110 investigate the causal relationship between various skin diseases and non-small cell lung cancer 111 (NSCLC). These methods provided a comprehensive analysis of potential genetic associations. 112 The IVW method was used to estimate the overall causal effect by combining the effects of all 113 selected SNPs, assuming no pleiotropy among genetic variants <sup>[18]</sup>. MR-Egger regression, by 114 relaxing the no-pleiotropy assumption, accounted for possible biases by allowing some 115 instrumental variables to influence the outcome through pathways other than the exposure [19], 116 The Weighted Median method, which requires that at least 50% of the total weight from genetic 117 variants be valid <sup>[20]</sup>. The Simple mode method offered stable estimates when dealing with a small 118 number of instrumental variables, while the Weighted mode method reduced bias caused by 119 heterogeneous effects among genetic variants <sup>[21]</sup>. Cochran's Q test assessed heterogeneity 120 among SNPs, with a P < 0.05 indicating the presence of heterogeneity, suggesting that genetic 121 variants may not be uniformly associated with the exposure or outcome. MR-Egger regression 122 was also used to test for horizontal and directional pleiotropy, with SNPs causing significant

5

- 123 pleiotropy (P < 0.05) being excluded to prevent bias <sup>[22]</sup>. Finally, A leave-one-out analysis was
- 124 conducted to systematically exclude each SNP individually, assessing the influence of each on
- 125 the overall association between exposure and outcome, ensuring no single SNP
- 126 disproportionately influenced the results.

## 127 **Results**

## 128 **3.1. Instrumental variable**

- 129 In the dataset of 26 skin diseases selected for this study, 7 datasets still could not obtain
- 130 sufficient instrumental variables even after lowering the inclusion and exclusion criteria. For 9
- 131 datasets, instrumental variables could only be obtained according to the reduced criterion of P <</p>
- 132 5 × 10-6. The remaining 10 datasets were able to obtain instrumental variables according to the
- 133 general standard. Among these, the number of instrumental variables for the skin diseases that
- 134 yielded positive results were as follows:
- 135 Dermatitis herpetiformis: 6
- 136 Acne: 5
- 137 Hidradenitis suppurativa: 3
- 138 Rhinophyma: 4
- 139 Notably, Rhinophyma could only obtain instrumental variables after lowering the significance
- 140 threshold to  $P < 5 \times 10-6$ , whereas the SNPs used for the other positive results all met the
- 141 criteria before the reduction. The positive results of the MR analysis are presented in Table 3,
- 142 while the heterogeneity and horizontal pleiotropy tests are shown in Table 2.

#### 143 **3.2.1. Dermatitis herpetiformis (DH) and NSCLC**

- 144 Mendelian Randomization (MR) analyses revealed a significant causal relationship between
- dermatitis herpetiformis (DH) and squamous cell carcinoma (SCC) of the lung. The analysis
- demonstrated robust associations with p-values: IVW P =  $0.0782 \times 10^{-4}$ , MR-Egger P = 0.2778,
- 147 Weighted Median (WM) P = 0.0004, Simple mode P = 0.0845, and Weighted mode P = 0.0258.

148 No heterogeneity was detected (Cochran's Q test P > 0.05), and the MR-Egger intercept test

- 149 confirmed no significant pleiotropy (P = 0.6038).
- 150 For adenocarcinoma (ADC), the causal association with DH was weaker, reflected in p-values:
- 151 IVW P = 0.0357, MR-Egger P = 0.2920, WM P = 0.0737, Simple mode P = 0.1908, and Weighted
- mode P = 0.1946. Cochran's Q test for ADC showed no heterogeneity (P > 0.05), and the MR-
- 153 Egger intercept test confirmed no significant pleiotropy (P = 0.6909). Leave-one-out analysis
- 154 confirmed that no single SNP disproportionately influenced the results. Scatter plots visually
- 155 confirmed the consistency and direction of these findings across all methods. (Fig. 2).

#### 156 **3.2.2. Acne (AC) and NSCLC**

- 157 Mendelian Randomization (MR) analyses indicated a specific association between acne (AC) and
- squamous cell carcinoma (SCC) of the lung. P-values across methods were: IVW P = 0.0321,

159 MR-Egger P = 0.2506, Weighted Median (WM) P = 0.0612, Simple mode P = 0.1997, and

160 Weighted mode P = 0.1852. Cochran's Q test (P > 0.05) confirmed no heterogeneity, and the

161 MR-Egger intercept test (P = 0.4230) showed no significant pleiotropy, supporting the reliability of

- 162 this association.
- 163 No causal relationship was found between AC and adenocarcinoma (ADC) of the lung, with all
- 164 methods yielding p-values greater than 0.05. Cochran's Q test (P > 0.05) and MR-Egger intercept
- 165 test (P = 0.8928) confirmed no heterogeneity or pleiotropy, reinforcing the conclusion that AC is
- not related to ADC. Scatter plots visually depicted the causal relationship between AC and
- 167 NSCLC (Fig. 3).

#### 168 **3.2.3. Hidradenitis suppurativa (HS) and NSCLC**

- 169 Mendelian Randomization (MR) analysis indicated a causal relationship between hidradenitis
- 170 suppurativa (HS) and lung adenocarcinoma (ADC), supported by p-values: IVW P = 0.0260, MR-
- Egger P = 0.5434, Weighted Median (WM) P = 0.0590, Simple mode P = 0.2014, and Weighted
- 172 mode P = 0.2244. Cochran's Q test (P > 0.05) indicated no heterogeneity, and the MR-Egger

173 intercept test (P = 0.7080) showed no significant pleiotropy, confirming the reliability of the HS-

174 ADC association.

- 175 No causal relationship was found between HS and squamous cell carcinoma (SCC) of the lung,
- with all methods yielding p-values greater than 0.05. The MR-Egger intercept test (P = 0.2834)
- 177 confirmed no significant pleiotropy, though the IVW Q test for SCC showed heterogeneity (P =
- 178 0.0062). This heterogeneity is less concerning due to the overall negative results for SCC. Leave-
- 179 one-out analysis identified a single SNP with significant impact, but removing it left only two
- 180 instrumental variables, insufficient for robust analysis. Scatter plots visually depicted the causal
- relationship between HS and NSCLC (Fig. 4).

#### 182 **3.2.4. Rhinophyma (RHN) and NSCLC**

- 183 Mendelian Randomization (MR) analyses suggested a potential causal relationship between
- rhinophyma (RHN) and adenocarcinoma (ADC) of the lung, with p-values: IVW P = 0.0382, MR-
- Egger P = 0.7349, Weighted Median (WM) P = 0.1433, Simple mode P = 0.4288, and Weighted
- mode P = 0.2913. Cochran's Q test (P > 0.05) indicated no significant heterogeneity, and the MR-
- 187 Egger intercept test (P = 0.7095) showed no significant pleiotropy.One SNP significantly
- impacted the results in the leave-one-out analysis, but only the IVW method retained a p-value
- 189 below 0.05 after exclusion.
- 190 No causal relationship was found between RHN and squamous cell carcinoma (SCC), with all
- 191 methods yielding p-values greater than 0.05. Cochran's Q test (P > 0.05) and MR-Egger test (P =
- 192 0.4915) confirmed no heterogeneity or pleiotropy. Scatter plots illustrated these relationships (Fig.
- 193 5). The association between RHN and ADC should be interpreted with caution due to the reliance
- 194 on a lowered significance threshold.

#### 195 **3.2.5. The remaining 15 skin conditions and NSCLC**

- 196 The remaining 15 skin conditions showed no association with the two types of NSCLC (all
- analysis methods P > 0.05). For datasets where the leave-one-out analysis revealed that certain
- 198 SNPs interfered with the results, a new MR analysis was performed after removing the

corresponding SNPs. The analysis conducted after removing the corresponding SNPs still failedto yield positive results.

## 201 **Discussion**

202 In modern life sciences research, both the lungs and the skin originate from the mesoderm,

203 indicating a shared homology in their growth and development <sup>[23]-[24].</sup> Pathophysiological studies

204 have further confirmed the connection between the two. For example, in mucosal immunity,

secretory immunoglobulin A (slgA) serves as a key effector molecule. Research has shown its

varying levels of expression in diseases such as asthma and chronic urticaria <sup>[25][26]</sup>. Some studies

focusing on the relationship between immunity, inflammation, and malignancy have identified key

208 pathways, including Toll-like receptors (TLRs) and the tumor microenvironment (TME), which

209 share inflammatory signals with skin diseases. For instance, cytokines such as TNF-α, IL-6, and

210 IL-1β play critical roles in both lung and skin inflammation, suggesting that there may be

211 mechanistic overlaps between pulmonary and dermatological conditions<sup>[6]</sup>. In NSCLC, commonly

212 used EGFR-TKI targeted drugs frequently cause skin rashes as the most common side effect.

213 Current research on EGFR-TKI-related rashes suggests that the primary cause of these rashes is

the disruption of the EGFR pathway, leading to interference with keratinocyte growth, migration,

215 proliferation, and differentiation<sup>[27]</sup>.

216 Recent MR studies on psoriasis and lung cancer published over the past two years <sup>[8]-[9]</sup> have

bolstered our confidence in exploring this area further. Consequently, our team, building on these

studies and leveraging the updated FinnGen R11 dataset from June 2024, selected 26 skin

diseases as instrumental variables to investigate the relationship between skin diseases and non small cell lung cancer.

221 Regarding the four skin diseases that yielded positive results: Dermatitis herpetiformis, Acne,

Hidradenitis suppurativa, and Rhinophyma.

223 Dermatitis herpetiformis (DH) is characterized by blistering rashes, often accompanied by intense

itching, and frequently co-occurs with celiac disease. Previous studies have identified a significant

association between DH and the development of malignancies. A 2012 cohort study, with a 25-

226 year follow-up, concluded that DH was significantly linked to the incidence of visceral and

lymphatic tumors <sup>[28]-[29]</sup>. However, few further in-depth studies have been conducted on this topic
since then.

229 For Acne, there are a few reports linking it with malignancies such as breast cancer and prostate

230 cancer. However, no other studies have clearly elucidated the relationship between Acne and

231 lung cancer <sup>[30]-[31]</sup>.

Hidradenitis suppurativa (HS) has been associated with lymphoma <sup>[32]</sup> and skin malignancies in

previous studies. Approximately 0.5% to 4.6% of HS patients have later been diagnosed with

234 cutaneous squamous cell carcinoma <sup>[33]</sup>. Additionally, a systematic review encompassing 2,795

articles demonstrated an association between HS and psoriasis, indicating shared inflammatory

236 pathways such as the IL-12-IL-23 axis, IL-17 interactions, and tumor necrosis factor (TNF)-α<sup>[34]</sup>.

237 Previous studies have confirmed the association between psoriasis and the risk of lung cancer [8]-

<sup>[9]</sup>. Therefore, the correlation between HS and NSCLC is supported by existing research.

239 Rhinophyma is generally considered an advanced manifestation of Rosacea. Currently, research

specifically on Rhinophyma is limited, but studies on Rosacea have confirmed its association with

an increased risk of skin and breast malignancies, particularly showing a significant correlation

242 with HER2-negative breast cancer<sup>[35]-[36]</sup>.

243 The MR analysis provides new evidence on the relationship between four skin diseases

244 (Dermatitis herpetiformis, Acne, Rhinophyma, and Hidradenitis suppurativa) and the risk of

NSCLC. However, the study has limitations, To ensure the consistency of the study population,

we can currently only choose data with a predominantly European population. Additionally,

247 although the causal relationships were analyzed using genetic instrumental variables, the results

show that, apart from Dermatitis herpetiformis, the other three skin diseases are only associated

249 with one type of NSCLC. Further research is needed to understand the specific relationships and

250 patterns between different skin diseases and NSCLC subtypes. In addition, after the relevant

251 genomic studies are further refined, further studies in Asian populations are needed to compare

the results with the present study.

253

10

## 254 Conclusion

- 255 This study confirms the association between four skin diseases and the risk of NSCLC. Dermatitis
- 256 herpetiformis is significantly associated with an increased risk of squamous cell carcinoma of the
- 257 lung. Acne shows a nominal association with an increased risk of squamous cell carcinoma of the
- 258 lung. Rhinophyma, Hidradenitis suppurativa, and Dermatitis herpetiformis also exhibit nominal
- associations with an increased risk of adenocarcinoma of the lung. These findings provide
- 260 direction for future clinical and experimental research related to NSCLC and highlight the
- 261 importance of NSCLC screening and prevention in patients with these conditions. The fifteen skin
- diseases not found to be associated with NSCLC can help guide future research away from
- 263 unrelated areas. Further genomic studies are necessary for the seven skin diseases for which
- sufficient SNP data were not obtained.

## 265 Acknowledgments

266 We thank FinnGen database for their contributions.

## 267 Data availability

268 The dataset in this study can be found in the FinnGen database.

## 269 **Consent for publication**

Not applicable.

## 271 Funding

- 272 This study was partially supported by the 2024 Traditional Chinese Medicine Research Program
- of Hunan Provincial Administration of Traditional Chinese Medicine (Grant Number: D2024032).

## 274 **Competing interests**

275 The author(s) report no conflicts of interest in this work.

## 276 **References**

- [1] Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non-Small Cell Lung Cancer in the US. JAMA Oncol. 2021
   Dec 1;7(12):1824-1832. doi: 10.1001/jamaoncol.2021.4932. PMID: 34673888; PMCID: PMC8532041.
- [2] Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, Faramarzi F,
   Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan-Sigari R. Recent advances in non small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023 Aug
   11;23(1):162. doi: 10.1186/s12935-023-02990-y. PMID: 37568193; PMCID: PMC10416536.
- [3] Rodak O, Peris-Díaz MD, Olbromski M, Podhorska-Okołów M, Dzięgiel P. Current Landscape
  of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies,
  and Immunotherapy. Cancers (Basel). 2021 Sep 20;13(18):4705. doi:
  10.3390/cancers13184705. PMID: 34572931; PMCID: PMC8470525.
- [4] Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017 Jun;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004.
   PMID: 28583445.
- Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer.
   J Clin Invest. 2007 May;117(5):1175-83. doi: 10.1172/JCI31537. PMID: 17476347; PMCID: PMC1857251.
- Subudhi I, Konieczny P, Prystupa A, Castillo RL, Sze-Tu E, Xing Y, Rosenblum D, Reznikov I,
  Sidhu I, Loomis C, Lu CP, Anandasabapathy N, Suárez-Fariñas M, Gudjonsson JE, Tsirigos
  A, Scher JU, Naik S. Metabolic coordination between skin epithelium and type 17 immunity
  sustains chronic skin inflammation. Immunity. 2024 Jul 9;57(7):1665-1680.e7. doi:
  10.1016/j.immuni.2024.04.022. Epub 2024 May 20. PMID: 38772365; PMCID: PMC11236527.
- [7] Budisan L, Zanoaga O, Braicu C, Pirlog R, Covaliu B, Esanu V, Korban SS, Berindan-Neagoe
   I. Links between Infections, Lung Cancer, and the Immune System. Int J Mol Sci. 2021 Aug
   30:22(17):9394. doi: 10.3390/iims22179394. PMID: 34502312; PMCID: PMC8431665.
- Luo Q, Chen J, Qin L, Luo Y, Zhang Y, Yang X, Wang H. Psoriasis may increase the risk of lung cancer: a two-sample Mendelian randomization study. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2113-2119. doi: 10.1111/jdv.18437. Epub 2022 Jul 28. PMID: 35844064.
- Wang X, Wang X, Wang H, Yang M, Dong W, Shao D. Association between psoriasis and lung
   cancer: two-sample Mendelian randomization analyses. BMC Pulm Med. 2023 Jan 5;23(1):4.
   doi: 10.1186/s12890-022-02297-0. PMID: 36604675; PMCID: PMC9814449.
- [10] Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, 310 311 Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G, Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas 312 I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, 313 Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, 314 315 Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, 316 Andersson B, Alenius H. Microbe-host interplay in atopic dermatitis and psoriasis. Nat Commun. 317 2019 Oct 16;10(1):4703. doi: 10.1038/s41467-019-12253-y. PMID: 31619666; PMCID: PMC6795799. 318
- [11] Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K,
   Popat UR, Shpall EJ, Champlin RE, Oran B. Significance of minimal residual disease
   monitoring by real-time quantitative polymerase chain reaction in core binding factor acute
   myeloid leukemia for transplantation outcomes. Cancer. 2020 May 15;126(10):2183-2192. doi:

- 323 10.1002/cncr.32769. Epub 2020 Feb 26. PMID: 32101640.
- [12] P. Sekula, M.F. Del Greco, C. Pattaro, et al., Mendelian randomization as an approach to
   assess causality using observational data, J. Am. Soc. Nephrol. 27 (11) (2016) 3253–3265,
   https://doi.org/10.1681/ASN.2016010098.
- [13] L. Li, Q. Ren, Q. Zheng, et al., Causal associations between gastroesophageal reflux disease
   and lung cancer risk: a Mendelian randomization study, Cancer Med. 12 (6) (2023) 7552–7559,
   https://doi.org/10.1002/cam4.5498. /
- [14] K. Lee, C.Y. Lim, Mendelian randomization analysis in observational epidemiology, J Lipid
   Atheroscler 8 (2) (2019) 67–77, <a href="https://doi.org/10.12997/jla.2019.8.2.67">https://doi.org/10.12997/jla.2019.8.2.67</a>.
- [15] E. Birney, Mendelian randomization, Cold Spring Harb Perspect Med. 12 (4) (2022) a041302,
   <u>https://doi.org/10.1101/cshperspect.a041302</u>.
- [16] J.A. de Klerk, J.W.J. Beulens, H.L. Mei, et al., Altered blood gene expression in the obesity related type 2 diabetes cluster may be causally involved in lipid metabolism: a Mendelian
   randomization study, Diabetologia 66 (6) (2023) 1057–1070, <a href="https://doi.org/10.1007/s00125-023-05886-8">https://doi.org/10.1007/s00125-023-05886-8</a>.
- [17] Xu L, Li H, Liu B, Han X, Sun H. Systemic Inflammatory Regulators Associated with
   Osteoporosis: A Bidirectional Mendelian Randomization Study. Calcif Tissue Int. 2024
   May;114(5):490-501. doi: 10.1007/s00223-024-01200-9. Epub 2024 Mar 25. PMID: 38528199.
- [18] J. Bowden, M.F. Del Greco, C. Minelli, et al., Assessing the suitability of summary data for two sample Mendelian randomization analyses using MR-Egger regression: the role of the I2
   statistic, Int. J. Epidemiol. 45 (6) (2016) 1961–1974, https://doi. org/10.1093/ije/dyw220.
- [19] S. Burgess, S.G. Thompson, Interpreting findings from Mendelian randomization using the MR Egger method, Eur. J. Epidemiol. 32 (5) (2017) 377–389, https://doi. org/10.1007/s10654-017 0255-x.
- J. Bowden, G. Davey Smith, S. Burgess, Mendelian randomization with invalid instruments:
   effect estimation and bias detection through Egger regression, Int. J. Epidemiol. 44 (2) (2015)
   512–525, <u>https://doi.org/10.1093/ije/dyv080</u>.
- [21] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort
   data. Am J Hum Genet. 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub
   2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- [22] Fife JD, Cassa CA. Estimating clinical risk in gene regions from population sequencing cohort
   data. Am J Hum Genet. 2023 Jun 1;110(6):940-949. doi: 10.1016/j.ajhg.2023.05.003. Epub
   2023 May 25. PMID: 37236177; PMCID: PMC10257006.
- [23] Chinoy MR. Lung growth and development. Front Biosci. 2003 Jan 1;8:d392-415. doi:
   10.2741/974. PMID: 12456356.
- [24] Visscher M, Narendran V. The Ontogeny of Skin. Adv Wound Care (New Rochelle). 2014 Apr
   1;3(4):291-303. doi: 10.1089/wound.2013.0467. PMID: 24761361; PMCID: PMC3985523.
- [25] de Fays C, Carlier FM, Gohy S, Pilette C. Secretory Immunoglobulin A Immunity in Chronic
   Obstructive Respiratory Diseases. Cells. 2022 Apr 13;11(8):1324. doi: 10.3390/cells11081324.
   PMID: 35456002; PMCID: PMC9027823.
- [26] Corthésy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol. 2013
   Jul 12;4:185. doi: 10.3389/fimmu.2013.00185. PMID: 23874333; PMCID: PMC3709412.
- [27] Chen C B, Wu M Y, Ng C Y, et al. Severe cutaneous adverse reactions induced by ta rgeted
   anticancer therapies and immunotherapies[J]. Cancer Manag Res, 2018,10:1 259-1273.
- 367 [28] Sneddon IB. Cutaneous manifestations of visceral malignancy. Postgrad Med J. 1970
   368 Nov;46(541):678-85. doi: 10.1136/pgmj.46.541.678. PMID: 4924274; PMCID: PMC2467095.
- [29] Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RF. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther. 2012 Mar;35(6):730-9. doi: 10.1111/j.1365-2036.2012.04998.x. Epub 2012 Jan 30. PMID: 22288441.
- [30] Ugge H, Udumyan R, Carlsson J, Andrén O, Montgomery S, Davidsson S, Fall K. Acne in late
   adolescence and risk of prostate cancer. Int J Cancer. 2018 Apr 15;142(8):1580-1585. doi:
   10.1002/ijc.31192. Epub 2017 Dec 14. PMID: 29205339; PMCID: PMC5838533.
- 376 [31] Murphy JD, Sandler D, White AJ, O'Brien KM. Severe acne and risk of breast cancer. Breast
- 377 Cancer Res Treat. 2019 Sep;177(2):487-495. doi: 10.1007/s10549-019-05302-z. Epub 2019

- 378 Jun 5. PMID: 31165375; PMCID: PMC6771926.
- [32] Tannenbaum R, Strunk A, Garg A. Association Between Hidradenitis Suppurativa and Lymphoma. JAMA Dermatol. 2019 May 1;155(5):624-625. doi: 10.1001/jamadermatol.2018.5230. PMID: 30698627; PMCID: PMC6506877.
- [33] Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am
   Acad Dermatol. 2015 Nov;73(5 Suppl 1):S27-35. doi: 10.1016/j.jaad.2015.07.055. PMID:
   26470611.
- [34] Gau SY, Preclaro IAC, Wei JC, Lee CY, Kuan YH, Hsiao YP, Juang SE, Ma KS. Risk of psoriasis in people with hidradenitis suppurativa: A systematic review and meta-analysis. Front Immunol. 2022 Dec 1;13:1033844. doi: 10.3389/fimmu.2022.1033844. PMID: 36532043;
   PMCID: PMC9752046.
- [35] Luo M, Wei B. Novel insights into rosacea's role in cancer risk: A Mendelian randomization
   approach. Skin Res Technol. 2024 May;30(5):e13737. doi: 10.1111/srt.13737. PMID:
   38769705; PMCID: PMC11106556.
- [36] Li WQ, Zhang M, Danby FW, Han J, Qureshi AA. Personal history of rosacea and risk of
   incident cancer among women in the US. Br J Cancer. 2015 Jul 28;113(3):520-3. doi:
   10.1038/bjc.2015.217. Epub 2015 Jun 23. PMID: 26103573; PMCID: PMC4522627.
- 396 **Table 1**

395

- 397 The information on skin diseases and non-small cell lung cancer data used in this study, all of
- 398 which can be obtained from the FinnGen database, includes the following:
- 399 Lung Cancers: Lung Squamous Cell Carcinoma (SCC), Lung Adenocarcinoma (ADC),
- 400 Skin Diseases: Acne (AC), Hidradenitis Suppurativa (HS), Dermatitis Herpetiformis (DH),
- 401 Infective Dermatitis (ID), Localized Scleroderma (LS), Cutaneous Abscess, Furuncle, and
- 402 Carbuncle (CA), Atrophic Disorders of Skin (ADS), Papulosquamous Disorders (PSD), Atopic
- 403 Dermatitis (AD), Urticaria (URT), Rhinophyma (RHN), Acquired Keratosis Palmaris et Plantaris
- 404 (AKD), Pityriasis Lichenoides Chronica (PLC), Pityriasis Rosea (PR), Pyoderma (PYD), Xerosis
- 405 Cutis (XER), Pruritus (PRU), Pemphigus (PEM), Seborrhoeic Dermatitis (SD), Pityriasis Rubra
- 406 Pilaris (PRP), Lichen Planopilaris (LPP), Acne Conglobata (ACC), Erythema Multiforme (EM),
- 407 Lupus Erythematosus (SLE), Chloasma (CHL), and Pigmented Purpuric Dermatosis (PPD).

| Trait | N.cases | N.controls | Populations | Year | Filtering threshold       |
|-------|---------|------------|-------------|------|---------------------------|
| SCC   | 1787    | 345118     | European    | 2024 | -                         |
| ADC   | 2064    | 345118     | European    | 2024 | -                         |
| AC    | 3982    | 432686     | European    | 2024 | P < 5 × 10 <sup>-8</sup>  |
| HS    | 1209    | 432686     | European    | 2024 | P < 5 × 10 <sup>-8</sup>  |
| DH    | 585     | 451899     | European    | 2024 | P < 5 × 10 <sup>- 8</sup> |
| ID    | 4195    | 394476     | European    | 2024 | P < 5 × 10 <sup>- 8</sup> |
| LS    | 450     | 423041     | European    | 2024 | P < 5 × 10 <sup>-8</sup>  |

| CA  | 10296 | 426987 | European | 2024 | P < 5 × 10 <sup>− 8</sup> |
|-----|-------|--------|----------|------|---------------------------|
| ADS | 5037  | 423041 | European | 2024 | P < 5 × 10 <sup>− 8</sup> |
| PSD | 16313 | 437420 | European | 2024 | P < 5 × 10 <sup>− 8</sup> |
| AD  | 26905 | 394476 | European | 2024 | P < 5 × 10 <sup>− 8</sup> |
| URT | 12576 | 438050 | European | 2024 | P < 5 × 10 <sup>− 8</sup> |
| RHN | 175   | 432686 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| AKD | 137   | 423041 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| PLC | 122   | 437420 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| PR  | 242   | 437420 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| PYD | 643   | 426987 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| XER | 429   | 423041 | European | 2024 | P < 5 × 10 <sup>− 6</sup> |
| PRU | 3819  | 394476 | European | 2024 | P < 5 × 10 <sup>− 6</sup> |
| PEM | 208   | 451899 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| SD  | 3382  | 394476 | European | 2024 | P < 5 × 10 <sup>-6</sup>  |
| PRP | 71    | 437420 | European | 2024 | Insufficient data         |
| LPP | 83    | 432686 | European | 2024 | Insufficient data         |
| ACC | 175   | 432686 | European | 2024 | Insufficient data         |
| EM  | 754   | 438050 | European | 2024 | Insufficient data         |
| SLE | 777   | 423041 | European | 2024 | Insufficient data         |
| CHL | 127   | 423041 | European | 2024 | Insufficient data         |
| PPD | 289   | 423041 | European | 2024 | Insufficient data         |

408 **Table 2** 

410 Acne (AC), Hidradenitis suppurativa (HS), and Rhinophyma (RHN). Lung Squamous Cell

411 Carcinoma (SCC) and adenocarcinoma of the lung (ADC)

| Exposure | Outcome | Hete       | Heterogeneity |                 |  |
|----------|---------|------------|---------------|-----------------|--|
|          |         | MR Egger Q | IVW Q         | Egger intercept |  |
|          |         | (P)        | (P)           | (P)             |  |
| DH       | SCC     | 4.6051     | 4.9693        | 0.6038          |  |
|          |         | (0.3302)   | (0.4196)      |                 |  |
| AC       |         | 2.0474     | 2.9035        | 0.4230          |  |
|          |         | (0.5626)   | (0.5740)      |                 |  |
| HS       |         | 1.8801     | 10.1380       | 0.2834          |  |
|          |         | (0.1703)   | (0.0062)      |                 |  |
| RHN      |         | 0.4662     | 1.1637        | 0.4915          |  |
|          |         | (0.7920)   | (0.7617)      |                 |  |

<sup>409</sup> Pleiotropy and heterogeneity test of the MR positive results, including Dermatitis herpetiformis (DH),

| DH  | ADC | 4.5910   | 4.8008   | 0.6909 |
|-----|-----|----------|----------|--------|
|     |     | (0.3318) | (0.4406) |        |
| AC  |     | 0.9011   | 0.9226   | 0.8928 |
|     |     | (0.8251) | (0.9212) |        |
| HS  |     | 0.0235   | 0.2673   | 0.7080 |
|     |     | (0.8779) | (0.8748) |        |
| RHN |     | 1.9837   | 2.1679   | 0.7095 |
|     |     | (0.3708) | (0.5382) |        |
|     |     |          |          |        |

412

#### 413 **Table 3**

414 MR analysis results of skin diseases with positive associations and non-small cell lung cancer,

415 including Dermatitis herpetiformis (DH), Acne (AC), Hidradenitis suppurativa (HS), and

416 Rhinophyma (RHN), with Lung Squamous Cell Carcinoma (SCC) and adenocarcinoma of the


417 lung (ADC).


| Exposure | Outcome | MR methods    | No<br>SNPs | OR (95% CI)           | 1             | Р                       |
|----------|---------|---------------|------------|-----------------------|---------------|-------------------------|
| DH       | SCC     | MR Egger      | 6          | 1.09 (0.955 - 1.24)   | +-            | 0.2778                  |
|          |         | WM            | 6          | 1.12 (1.05 - 1.19)    | +             | 0.0004                  |
|          |         | IVW           | 6          | 1.12 (1.07 - 1.18)    | +             | 0.0782×10 <sup>-4</sup> |
|          |         | Simple mode   | 6          | 1.10 (1.01 - 1.21)    | -             | 0.0845                  |
|          |         | Weighted mode | 6          | 1.12 (1.04 - 1.20)    | +             | 0.0258                  |
| AC       |         | MR Egger      | 5          | 1.85 (0.7901 - 4.37)  |               | 0.2506                  |
|          |         | WM            | 5          | 1.29 (0.9880 - 1.68)  |               | - 0.0612                |
|          |         | IVW           | 5          | 1.26 (1.0196 - 1.55)  | <b>⊢</b> ⊷    | 0.0321                  |
|          |         | Simple mode   | 5          | 1.35 (0.9202 - 1.98)  | +             | 0.1997                  |
|          |         | Weighted mode | 5          | 1.35 (0.9350 - 1.94)  |               | 0.1852                  |
| HS       |         | MR Egger      | 3          | 0.269 (0.0720 - 1.00) |               | 0.3007                  |
|          |         | WM            | 3          | 0.942 (0.7440-1.19)   |               | 0.6235                  |
|          |         | IVW           | 3          | 1.070 (0.7380-1.56)   |               | 0.7080                  |
|          |         | Simple mode   | 3          | 0.887 (0.6730 - 1.17) |               | 0.4866                  |
|          |         | Weighted mode | 3          | 0.903 (0.7060-1.15)   | + <u>+</u>    | 0.5021                  |
| RHN      |         | MR Egger      | 4          | 0.879 (0.6909 - 1.12) | -+-           | 0.4054                  |
|          |         | WM            | 4          | 0.989 (0.8860 - 1.11) |               | 0.8514                  |
|          |         | IVW           | 4          | 0.967 (0.8832-1.06)   | +             | 0.4697                  |
|          |         | Simple mode   | 4          | 0.991 (0.8584 - 1.15) | - <b>+</b> -  | 0.9166                  |
|          |         | Weighted mode | 4          | 0.995 (0.8814 - 1.12) | _ <b>∔</b>    | 0.9363                  |
| DH       | ADC     | MR Egger      | 6          | 1.08 (0.954 - 1.22)   | + <b>-</b> -  | 0.2920                  |
|          |         | WM            | 6          | 1.05 (0.995 - 1.11)   | •             | 0.0737                  |
|          |         | IVW           | 6          | 1.05 (1.00 - 1.11)    | +             | 0.0357                  |
|          |         | Simple mode   | 6          | 1.08 (0.978 - 1.19)   | +             | 0.1908                  |
|          |         | Weighted mode | 6          | 1.05 (0.985 - 1.12)   | •             | 0.1946                  |
| AC       |         | MR Egger      | 5          | 0.83 (0.3774 - 1.84)  | •             | 0.6809                  |
|          |         | WM            | 5          | 0.89 (0.7135 - 1.13)  | -+ <u>+</u> - | 0.3666                  |
|          |         | IVW           | 5          | 0.88 (0.7269 - 1.07)  | -+-           | 0.2018                  |
|          |         | Simple mode   | 5          | 0.90 (0.6530 - 1.24)  |               | 0.5553                  |
|          |         | Weighted mode | 5          | 0.89 (0.6643 - 1.21)  |               | 0.5276                  |
| HS       |         | MR Egger      | 3          | 0.671 (0.2740-1.65)   | •             | - 0.5434                |
|          |         | WM            | 3          | 0.832 (0.6870-1.01)   |               | 0.0590                  |
|          |         | IVW           | 3          | 0.838 (0.7180-0.979)  | -             | 0.0260                  |
|          |         | Simple mode   | 3          | 0.818 (0.6620-1.01)   |               | 0.2014                  |
|          |         | Weighted mode | 3          | 0.822 (0.6590-1.03)   |               | 0.2244                  |
| RHN      |         | MR Egger      | 4          | 1.044 (0.8384 - 1.30) |               | 0.7349                  |
|          |         | WM            | 4          | 1.084 (0.9739 - 1.21) | +             | 0.1433                  |
|          |         | IVW           | 4          | 1.092 (1.0047 - 1.19) | -             | 0.0382                  |
|          |         | Simple mode   | 4          | 1.072 (0.9347 - 1.23) | +             | 0.4288                  |
|          |         | Weighted mode | 4          | 1.082 (0.9498 - 1.23) | +             | .0.2913                 |


418


419

420 **Figure 1**. The flowchart of the study.











433



Obtain datasets for skin diseases (exposure) and lung squamous cell carcinoma; lung adenocarcinoma (outcome) from the FinnGen

Select appropriate genetic instrumental variables (GIVs) for skin diseases  $(p<5\times10^{-8}, r^{2}<0.001, window size=10000kb, minor allele frequency MAF > 0.01; removal of SNPs associated with non-small cell lung cancer. If sufficient SNPs cannot be obtained under the <math>p<5\times10^{-8}$  threshold, the standard will be relaxed to  $p<5\times10^{-6}$ .



Removal of potentially pleiotropic SNPs⊌ DH and AC \_\_\_\_\_ SCC 15 skin diseases showed no statistically significant association with NSCLC

# Figure